Nayan Lamba
YOU?
Author Swipe
View article: RADT-53. IMPACT OF SMALLER CLINICAL TARGET VOLUME EXPANSIONS FOR THE RADIATION TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
RADT-53. IMPACT OF SMALLER CLINICAL TARGET VOLUME EXPANSIONS FOR THE RADIATION TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA Open
BACKGROUND With advances in image-guidance, there has been interest in smaller clinical target volume (CTV) expansions for radiation therapy planning in glioblastoma. We reviewed the impact of varying CTV expansion margins on patterns of r…
View article: Brain imaging screening in metastatic breast cancer: Is it time to rethink clinical guidelines and practice?
Brain imaging screening in metastatic breast cancer: Is it time to rethink clinical guidelines and practice? Open
View article: Toxicities Associated with Adjuvant Radiation Therapy in Atypical Meningioma
Toxicities Associated with Adjuvant Radiation Therapy in Atypical Meningioma Open
View article: Genomic Predictors of Leptomeningeal Disease Development among Patients with Brain Metastases
Genomic Predictors of Leptomeningeal Disease Development among Patients with Brain Metastases Open
View article: A genomic score to predict local control among patients with brain metastases managed with radiation
A genomic score to predict local control among patients with brain metastases managed with radiation Open
Background Clinical predictors of local recurrence following radiation among patients with brain metastases (BrM) provide limited explanatory power. We developed a DNA-based signature of radiotherapeutic efficacy among patients with BrM to…
View article: Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries
Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries Open
Background Leptomeningeal disease (LMD) is a relatively uncommon manifestation of advanced cancer. Patients with LMD carry a poor prognosis and often decline rapidly, complicating inclusion in clinical trials. Identification of LMD subsets…
View article: Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era Open
Following anti-PD-1 approval in 2015, first-line ICI was associated with substantial OS improvements for patients with stage IV melanoma, including those with brain metastases. As of 2019, 38% of patients still were not receiving first-lin…
View article: Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions Open
Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is known about brain metastases than cancer-related entities of similar incidence. Advances in oncologic care have heightened the importance of intracr…
View article: Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation
Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation Open
Background The optimal chemotherapy regimen between temozolomide and procarbazine, lomustine, and vincristine (PCV) remains uncertain for WHO grade 3 oligodendroglioma (Olig3) patients. We therefore investigated this question using nationa…
View article: Practice Variation in Perioperative Steroid Dosing for Brain Tumor Patients: An International Survey
Practice Variation in Perioperative Steroid Dosing for Brain Tumor Patients: An International Survey Open
Steroids are commonly used to treat peritumoral edema and increased intracranial pressure in patients with brain tumors. Despite widespread use of steroids, relatively little evidence is available about their optimal perioperative dosing s…
View article: Predictors of long-term survival among patients with brain metastases
Predictors of long-term survival among patients with brain metastases Open
Brain metastases (BrM) are common among patients with solid malignancies.1 The prognosis of patients with BrM has generally been poor, with population-based studies demonstrating survival times of ≤12 months for patients with BrM at cancer…
View article: EPID-17. COMPARATIVE EPIDEMIOLOGY OF PRIMARY BRAIN TUMORS AMONG ADOLESCENTS AND YOUNG ADULTS (AYA)
EPID-17. COMPARATIVE EPIDEMIOLOGY OF PRIMARY BRAIN TUMORS AMONG ADOLESCENTS AND YOUNG ADULTS (AYA) Open
INTRODUCTION We utilized national registry data to evaluate the unique epidemiology of primary adolescent and young adult (AYA) brain tumors according to the WHO2016 classification. METHODS AYA patients (15≤age≤39) presenting between 2004-…
View article: EPID-01. THE EPIDEMIOLOGY OF BRAIN METASTASES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS DISTINCTLY DIFFERS FROM THE ADULT POPULATION
EPID-01. THE EPIDEMIOLOGY OF BRAIN METASTASES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS DISTINCTLY DIFFERS FROM THE ADULT POPULATION Open
INTRODUCTION Few data exist regarding the epidemiology of brain metastases (BMs) in adolescent and young adult (AYA) patients. Herein we use national cancer registry data to dissect their epidemiology and compare to the adult population. M…
View article: NCOG-03. PREDICTORS OF NEUROLOGIC DEATH IN PATIENTS WITH BRAIN METASTASES
NCOG-03. PREDICTORS OF NEUROLOGIC DEATH IN PATIENTS WITH BRAIN METASTASES Open
BACKGROUND Neurologic death (ND), defined as intracranial disease progression with accompanying neurologic symptoms in the absence of life-threatening systemic disease, is the most serious consequence of intracranial disease among patients…
View article: Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis
Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis Open
Background Falls in patients with cancer harbor potential for serious sequelae. Patients with brain metastases (BrM) may be especially susceptible to falls but supporting investigations are lacking. We assessed the frequency, etiologies, r…
View article: 246 Effectiveness and utilization of first-line immune checkpoint inhibitors for patients with extracranial & intracranial metastatic melanoma
246 Effectiveness and utilization of first-line immune checkpoint inhibitors for patients with extracranial & intracranial metastatic melanoma Open
Background We previously demonstrated the effectiveness of 2nd-line immune checkpoint inhibitors (ICI) for stage 4 melanoma patients.1 2In late 2015, ICI was FDA-approved and NCCN-recommended in the 1st-line setting.3 4
View article: Predictors of Long-Term Survival Among Patients With Brain Metastases
Predictors of Long-Term Survival Among Patients With Brain Metastases Open
View article: The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases
The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases Open
View article: GERM-04. PRIMARY INTRACRANIAL GERM CELL TUMORS ARE MORE PREVALENT AMONG PEDIATRIC PATIENTS OF ASIAN/PACIFIC ISLANDER RACE/ETHNICITY IN THE UNITED STATES
GERM-04. PRIMARY INTRACRANIAL GERM CELL TUMORS ARE MORE PREVALENT AMONG PEDIATRIC PATIENTS OF ASIAN/PACIFIC ISLANDER RACE/ETHNICITY IN THE UNITED STATES Open
Introduction Primary intracranial germ cell tumors (GCTs) appear to be more prevalent among pediatric patients in eastern Asia than in the U.S. Herein we use cancer registry data to evaluate whether GCT prevalence differs by race/ethnicity…
View article: RARE-25. DISSECTING THE CONTEMPORARY EPIDEMIOLOGY OF PRIMARY AND SECONDARY BRAIN TUMORS IN INFANCY THROUGH CHILDHOOD
RARE-25. DISSECTING THE CONTEMPORARY EPIDEMIOLOGY OF PRIMARY AND SECONDARY BRAIN TUMORS IN INFANCY THROUGH CHILDHOOD Open
Introduction Herein we utilize national registry data to evaluate the epidemiology of primary and secondary pediatric brain tumors according to the WHO2016 classification. Methods Pediatric patients (age≤14) presenting between 2004–2017 wi…
View article: Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis
Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis Open
Background Older patients with brain metastases (BrM) commonly experience symptoms that prompt acute medical evaluation. We characterized emergency department (ED) visits and inpatient hospitalizations in this population. Methods We identi…
View article: Epidemiology of brain metastases and leptomeningeal disease
Epidemiology of brain metastases and leptomeningeal disease Open
Brain metastases affect a significant percentage of patients with advanced extracranial malignancies. Yet, the incidence of brain metastases remains poorly described, largely due to limitations of population-based registries, a lack of man…
View article: Seizures Among Patients With Brain Metastases
Seizures Among Patients With Brain Metastases Open
The role of antiseizure medications among select patients with BrM should be re-explored, particularly for those with melanoma, a greater intracranial disease burden, or BrM in high-risk locations.
View article: Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non–Small Cell Lung Cancer
Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non–Small Cell Lung Cancer Open
The findings of this cohort study suggest that optimal cardiac dose constraints may differ based on preexisting CHD. Although the LAD coronary artery V15 Gy greater than or equal to 10% appeared to be an independent estimator of the probab…
View article: IMMU-04. IMMUNE-RELATED ADVERSE EVENTS STRONGLY PREDICT SUPERIOR OUTCOMES IN BRAIN METASTASES PATIENTS RECEIVING LOCAL TREATMENT AND IMMUNE CHECKPOINT INHIBITORS
IMMU-04. IMMUNE-RELATED ADVERSE EVENTS STRONGLY PREDICT SUPERIOR OUTCOMES IN BRAIN METASTASES PATIENTS RECEIVING LOCAL TREATMENT AND IMMUNE CHECKPOINT INHIBITORS Open
INTRODUCTION In several cancers treated with immune checkpoint inhibitors (ICIs), a remarkable association between the occurrence of immune-related adverse events (irAEs) and superior oncological outcomes has been reported. This effect has…
View article: 196 Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data
196 Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data Open
Background Management of advanced non-small cell lung carcinoma (NSCLC) has been transformed by PD-1/PD-L1 immune checkpoint inhibitors (ICI), with FDA approvals in 2015 (second-line) and 2016 (first-line). Despite ~40% of NSCLC patients d…
View article: RADT-21. NATIONAL PRACTICE PATTERNS AND OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY VS. CONVENTIONAL EXTERNAL BEAM RADIOTHERAPY FOR SPINAL METASTASES
RADT-21. NATIONAL PRACTICE PATTERNS AND OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY VS. CONVENTIONAL EXTERNAL BEAM RADIOTHERAPY FOR SPINAL METASTASES Open
INTRODUCTION Up to 10% of cancer patients experience spinal cord compression from metastatic disease. Palliation and local control were traditionally pursued with conventional external beam radiotherapy (cEBRT), but advancements in image-g…
View article: BIOM-06. CLINICAL AND PROGNOSTIC SIGNIFICANCE OF KRAS MUTATIONS FOR BRAIN METASTASES FROM COLORECTAL ADENOCARCINOMA IN THE UNITED STATES
BIOM-06. CLINICAL AND PROGNOSTIC SIGNIFICANCE OF KRAS MUTATIONS FOR BRAIN METASTASES FROM COLORECTAL ADENOCARCINOMA IN THE UNITED STATES Open
BACKGROUND KRAS mutations in colorectal adenocarcinomas have been associated with metastatic involvement of the brain (BM); and predict a lack of benefit to EGFR-targeted antibodies. Herein we leverage national data to evaluate the prevale…
View article: IMMU-02. THE SURVIVAL OUTCOMES ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS FOR NON-SMALL CELL LUNG CARCINOMA PATIENTS WITH BRAIN METASTASES IN THE UNITED STATES
IMMU-02. THE SURVIVAL OUTCOMES ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS FOR NON-SMALL CELL LUNG CARCINOMA PATIENTS WITH BRAIN METASTASES IN THE UNITED STATES Open
BACKGROUND Management of advanced NSCLC has been transformed by PD-1/PD-L1 immune checkpoint inhibitors (ICI), with FDA approvals in 2015 (second-line) and 2016 (first-line). Because patients with brain metastases (BMs) were disproportiona…
View article: MGMT Promoter Methylation is Predictive of Radiotherapy Outcomes for Newly-Diagnosed Glioblastomas and is not Prognostic in the Absence of Radiotherapy
MGMT Promoter Methylation is Predictive of Radiotherapy Outcomes for Newly-Diagnosed Glioblastomas and is not Prognostic in the Absence of Radiotherapy Open